钱多多股票论坛

trader1688.com
 FAQ FAQ RSS

支持168: Amazon Ebay Amazon(Canada)
Half


Post new topic Reply to topic  [ 544 Posts ]  Go to page Previous  1 ... 33, 34, 35, 36, 37  Next
Author Message
 Post subject: Re: 盘前个股动态2016
PostPosted: 8/28/17 22:14 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564
Gapping down
In reaction to disappointing earnings/guidance:

N/A
Other news:

EXPE -3.3% (Expedia CEO Dara Khosrowshahi is said to have been selected as Uber's (Private: UBER) next CEO, according to reports)
PRPH -2.2% (commences 4 mln share common stock tender offer at $2.30 per share)
SSW -1.9% (files for 6,928,697 Class A common shareoffering by the selling securityholders)
CDNA -0.9% (files for 2,814,299 share common stock by selling stockholders), .
Analyst comments:

NUVA -2.4% (downgraded to Underperform at Needham)


Gapping up
In reaction to strong earnings/guidance:

SNP +0.5%
M&A news:

KITE +28.9% (confirms agreement to be acquired by Gilead (GILD) for $180/share in cash)
GILD +1.1%
IXYS +42.6% (to be acquired by Littelfuse (LFUS) for $23.00/share)
Select metals/mining stocks trading higher:

AG +2.8%, AU +2.5%, HMY +2.2%, FCX +1.9%, SBGL +1.6%, NEM +1.4%, GG +1.3%, BBL +0.8%
Immuno-oncology stocks indicated higher premarket after Gilead (GILD) acquires Kite (KITE) for $12 bln:

JUNO +16.3%, BLUE +10.4%, CLLS +7.2%, INO +1.6%, TSRO +0.6%
Other news:

EYES +14% (receives conditional approval from the FDA to begin the Orion Cortical Visual Prosthesis System feasibility clinical study)
USAU +13.4% (reports summary results from its last four holes as part of its scout drilling program on the Keystone Project)
IDXG +11.5% (extended its agreement with LabCorp (LH) for two additional years until January 2019)
CRMD +6.8% (filed to withdraw Registration Statement on Form S-3 initially filed on August 26)
AVEO +6.1% (EC has approved FITVDA for treatment of adult patients with advanced renal cell carcinoma in the European Union plus Norway and Iceland)
LIFE +5.8% (enters into definitive securities purchase agreement with certain institutional and other accredited investors at $2.65/share)
LL +1.9% (related to Hurricane Harvey)
VIPS +1.8% (continued strength following M&A speculation late last week)
LOW +1.5% (related to Hurricane Harvey)
HD +1.2% (related to Hurricane Harvey)
BIIB +1% (reports results from a recently conducted analysis of the long-term extension of its ongoing Phase 1b study of aducanumabg)
AZN +0.9% (announced that the FDA has approved Faslodex)
Analyst comments:

APHB +11.5% (initiated with a Buy at H.C. Wainwright)
TTPH +5.7% (initiated with a Overweight at Piper Jaffray
VNTR +2.1% (initiated with a Buy at Goldman)


 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 8/29/17 22:14 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564
Gapping up In reaction to strong earnings/guidance: HAIN +14.6%, CTLT +13.1%, BBY +3.1%, JILL +0.6%, SHLO +0.5% Select metals/mining stocks trading higher with Gold Futures +0.8% after N Korea's missile launch toward Japan: HMY +5.9%, AU +4.2%, IAG +3.5%, AUY +3.4%, KGC +3.4%, GFI +3%, EXK +2.4%, NG +2.1%, GG +2%, AG +2%, ABX +1.9%, GOLD +1.6%, GDX +1.6%, NEM +1.6% Other news: IMGN +11.3% (Immunogen and Jazz Pharmaceuticals (JAZZ) have entered into a collaboration granting Jazz rights to opt into development and commercialization of two early-stage, hematology-related antibody-drug conjugate (ADC) programs) ETRM +8.2% (announces that a cost-effectiveness study analyzing vBloc Therapy for the treatment of obesity was published in the American Journal of Managed Care on August 25) APRI +4.1% (files its resubmission of a NDA for Vitaros) COTY +3.7% (higher after several insider buy disclosures) BW +2.9% (Vintage Capital Management discloses 9.99% passive stake) SRNE +2.9% (resubmits NDA and responds to all of FDA comments related to the initial NDA submission for its lead product candidate, ZTlido) Analyst comments: JUNO +1% (upgraded to Outperform from Mkt Perform at Raymond James) Gapping down Briefing note - With S&P Futures down 0.5% and Nasdaq Futures down 0.8%, majority of stocks are trading lower. The following represent weakness on identified catalysts/news In reaction to disappointing earnings/guidance: FINL -29.3%, (releases prelim Q2 results, lowers FY18 guidance- sees Q2 sales of $469.4 mln vs. $477.8 mln Capital IQ Consensus Est, sees EPS of $0.08-0.12 vs. $0.38 consensus) SFUN -4.7%, PSEC -3%, NOAH -1.6% Select FINL peers/related names showing weakness: FL -3.5%, UA -2.4%, NKE -2%, DKS -1.7% Other news: ACOR -28% (received a Refusal to File letter from the FDA regarding its NDA for INBRIJA) KMDA -2.3% (discloses that the FDA issued a letter stating that it continues to have concerns and questions about the safety and efficacy of the Inhaled AAT) PAA -0.9% (Moody's downgraded Plains All American Pipeline LP.'s senior unsecured rating to Ba1 from Baa3) Analyst comments: NTLA -2.4% (downgraded to Neutral from Buy at Chardan Capital Markets) AVXS -2.3% (initiated with Reduce at Nomura) AMGN Amgen announces results from an exploratory virtual histology sub-study of the Repatha GLAGOV Phase 3 coronary intravascular ultrasound imaging trial that looked at coronary artery plaque composition (172.23 +0.45) While virtual histology demonstrated an increase in dense calcium in coronary artery plaques in both the statin and Repatha arms, it did not detect a statistically significant difference between the two treatment groups. However, the observed directional trend in increased dense calcium with corresponding reduction in low-density lipoprotein cholesterol (LDL-C) is consistent with findings from previous statin studies. The sub-study also showed reductions in LDL-C and percent atheroma volume (PAV) consistent with the primary GLAGOV results. AMGN Amgen announces new analysis from Repatha studies at the European Society of Cardiology Congress 2017 (172.23 +0.45) Nineteen percent of patients in the Repatha cardiovascular outcomes study had a prior history of non-hemorrhagic stroke (n=5,337). In this analysis, stroke patients treated with Repatha experienced a 56 percent mean reduction in LDL-C levels, compared to placebo (median LDL-C level of 29 mg/dL for patients on Repatha versus median LDL-C of 89 mg/dL for placebo; p<0.001). The study was statistically powered around the hard major adverse cardiovascular event (MACE) composite endpoint of first heart attack, stroke or cardiovascular death (key secondary composite endpoint) and found that adding Repatha to optimized statin therapy resulted in a statistically significant 20 percent (p<0.001) reduction in these events. The study also found a statistically significant 15 percent reduction (p<0.001) in the risk of the extended MACE composite (primary) endpoint, which included hospitalization for unstable angina, coronary revascularization, heart attack, stroke or cardiovascular death.


 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 8/30/17 22:53 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564
Gapping up
In reaction to strong earnings/guidance:

AVAV +10%, GSM +4.8%, CAL +3.2%, BOBE +0.5%
M&A news:

COL +1.7% (cont strength on UTX spec)
Other news:

MZOR +6.4% (Mazor Robotics and Medtronic (MDT) enter next phase of strategic partnership earlier than planned; triggers $40 mln third tranche investment in Mazor)
OHGI +5.9% (implements $500,000 secure messaging contract with Hong Kong customer; also announces issuance of stock to Principal Executive Officer Martin Ward as repayment for debt)
MDCO +5.3% (FDA approved Vabomere for adults with complicated urinary tract infections)
CUR +3.9% (continued strength after closing +12%)
FSNN +3.8% (after closing up more than 25% on the day)
ALIM +3.6% (Alimera Sciences signs a distribution agreement with Horus Pharma; Horus will serve as Alimera's exclusive distributor in France for ILUVIEN )
JUNO +3.5% (continued strength after KITE/GILD news)
VSI +3% (Director discloses the purchase of 40k shares at $5.50 )
IMGN +2% (extending yesterday's move higher on JAZZ news)
COL +1.7% (cont strength on UTX spec)
XON +1.4% (continued strength after closing near highs)
LLY +1% (Eli Lilly and Incyte (INCY) to resubmit the NDA for baricitinib before the end of January)
SFM +0.9% (CFO disclosed purchase of 7000 shares worth approx $138.6K)
AN +0.6% (authorized the repurchase of up to an additional $250 million of common stock)
Analyst comments:

ITCI +8.1% (upgraded to Buy from Neutral at Ladenburg Thalmann)
OLED +2.3% (initiated with a Buy at Deutsche Bank)
PSEC +1% (upgraded to Mkt Perform from Underperform at Raymond James)
CIEN +0.8% (upgraded to Buy from Neutral at Citigroup)
CHRW +0.7% (upgraded to Overweight from Equal-Weight at Stephens)

Gapping down
In reaction to disappointing earnings/guidance:

DY -18.9%, CHS -10.6%, FRO -8%, HRB -5.6%, SCSC -3.7%, OLLI -3.3%, SBGL -2.5%
Other news:

OTIC -80.8% (announces results for its AVERTS-1 Phase 3 clinical trial of OTIVIDEX in patients with Mnire's disease; missed primary endpoint and all key vertigo secondary endpoint)
XTNT -4.2% (CFO John Gandolfo tenders resignation)
DRYS -4.1% ( to launch its previously announced rights offering of shares of common stock)
ASML -1.1% (may be related to investor conference presentation)
Analyst comments:

COTY -0.9% (downgraded to Sell from Hold at Berenberg)
VNO -0.5% (downgraded to Hold from Buy at Stifel)


 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 8/31/17 21:19 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564
Gapping down
In reaction to disappointing earnings/guidance:

DRYS -21.1%, (DryShips reports huge Q2 loss, co also received a subpoena from the SEC)
SMTC -11.1%, GCO -9.8%, CIEN -7.4%, BOX -4.2%, CPB -4%, CTRP -3.9%, DG -3.8%, GEF -1.2%, FIVE -0.8%
Other news:
K
AMRN -0.8% (files lawsuit to prevent the import and sale into the United States of synthetic omega-3 products that are comprised predominantly of EPA and sold for use in, or as, dietary supplements, contending that, consistent with multiple FDA statements and actions, such products are illegal unapproved new drugs under U.S. law)
MVIS -0.5% (Microvision announces $3.15 mln investment from current shareholder; company sold 1.5 mln unregistered shares to private investor at a price of $2.10 per share)
Analyst comments:

ERIC -2.2% (downgraded to Hold at Danske Bank)
08:25 SCANX Gapping up

Gapping up
In reaction to strong earnings/guidance/SSS:

LE +19.1%, SCVL +16.1%, MEI +8.7%, BVXV +2.3%, TD +1.4%, COST +1.3%, (Aug comps), WDAY +0.9%, PAHC +0.7%, FRED +0.7%, (Aug comps), LEJU +0.6%
M&A news:

BKS +4.8% (Hearing strength attributed to renewed M&A speculation)
YUME +1.7% (RhythmOne said to be near a deal to acquire YuMe for $185 mln in cash and stock, according to SkyNews)
Other news:

NXTD +20% (says its FitPay subsidiary is powering the payment capabilities for the vvoactive 3, a new smartwatch by Garmin International (GRMN))
OTIC +7% (modest rebound after closing 80%+ lower y'day)
APRI +6.3% (notified by the FDA that it has acknowledged receipt of its recently resubmitted NDA for Vitaros and considers it a complete, class 2 response to the Company's 2008 action lette)
VVUS +4.4% (Vivus enters into a settlement agreement with Dr. Reddy's (RDY) resolving patent litigation related to Qsymia)
OTEX +2.8% (files mixed securities shelf offering )
APEN +2.6% ( announces CE Mark approval for the ORBERA365 Managed Weight Loss System)
AN +2% (continued strength)
EXPE +1.1% (confirms CFO Mark Okerstrom to succeed Dara Khosrowshahi as CEO; Khosrowshahi to remain on Expedia board)
MRCY +0.9% (Mercury received Aerospace Standard 9100 certification for its Mercury Defense Systems Advanced Design Centers)
AZN +0.8% (Phase III PACIFIC data reinforce potential of Imfinzi)
Analyst comments:

YY +4.5% (initiated with Buy at Goldman)
MOMO +4.1% (initiated with Buy at Goldman)
PTEN +1.9% (initiated with a Buy at Societe Generale)
FCAU +1.6% (target raised to $30.10 from $22.40 at Goldman)


 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 9/4/17 20:11 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564

Gapping up
In reaction to strong earnings/guidance
:

  • PANW+7.7%,NTNX+6.8%,AVIR+4.3%,

M&A news:

  • CAAS+1.5% (receives revised going-private proposal for $5.45/share)
  • ACOR+1% (adopts poison pill 'in response to the recent accumulations of significant portions of Acorda's outstanding Common Stock'), . 

Other news:

  • APVO+82.7% (Aptevo Therapeutics and MorphoSys end joint development and commercialization agreement for MOR209/ES414; Aptevo regains worldwide rights - preliminary phase I data show markedly lower anti-drug antibody titers; Aptevo Therapeutics also signs agreement for up to $74.5 million to sell hyperimmune commercial products; provides significant non-dilutive funding to execute R&D Strategy)
  • IOVA+11.3% ( FDA has granted Fast Track designation for LN-144, the Company's adoptive cell therapy using its TIL technology, for the treatment of advanced melanoma)
  • DRYS+2.9% (commencement of its previously announced rights offering )
  • THC+2.8% (commences Board refreshment process, implements shareholder rights plan to protect NOLs)
  • BGNE+1.6% (BeiGene to close strategic oncology collaboration with Celgene Corporation)
  • NKE+1.3% (following LULU results)
  • ETP+1.1% (announces FERC approval to put Phase 1A of the Rover Pipeline in service; natural gas service to begin from Cadiz to Defiance August 31)

Analyst comments:

  • N/A


Gapping down
In reaction to disappointing earnings/guidance
:

  • TECD-18.9%,AMBA-13.1%,COO-1.9%

Other news:

  • MGNX-8.5% (MacroGenics announces termination of duvortuxizumab collaboration and license agreement with Janssen)
  • PGNX-1.9% (Progenics Pharm announces study results that show treatment with AZEDRA produced clinically meaningful and durable responses across multiple study endpoints, including radiographic tumor response, tumor biomarker response, and overall survival), .

Analyst comments:

  • N/A.

This week's biggest % gainers/losers
The following are this week's top 20 percentage gainers and top 20 percentage losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top 20 % gainers
  • Healthcare:JUNO (41.92 +36.41%),BLUE(130.85 +33.73%),BLCM (10.72 +29.47%),KITE (178.05 +28%), CLLS(32.18 +27.75%),ADAP (6.58 +26.3%),CRIS (2.09 +25.15%),NTLA (21.51 +23.2%),ITCI (18.67 +22.27%),IMMU (12.59 +21.29%),MNKD (1.87 +20.65%),CORT (16.8 +19.74%)
  • Industrials:AVAV (49.15 +26.58%),BW (2.72 +23.08%),HEES (24.70 +21.73%),HTZ (20.74 +20.44%)
  • Consumer Discretionary:EROS (12.25 +33.88%)
  • Information Technology:HIMX (10.46 +20.79%)
  • Energy:CLMT (8.40 +28.24%)
This week's top 20 % losers
  • Healthcare:OTIC (3.6 -82.04%),ACOR (21.70 -13.72%),CO (13.32 -9.2%)
  • Materials:FRTA (3.34 -27.07%)
  • Industrials:TITN (12.10 -22.54%)
  • Consumer Discretionary:BNED (5.51 -21.06%),FINL (8.89 -16.68%),GCO (23.2 -16.4%),BBY (54.48 -11.94%),HRB (26.77 -9.9%), VRA(9.09 -9.46%),AOBC (16.52 -8.63%)
  • Information Technology:AMBA (42.24 -20.27%),TECD (87.46 -17.82%),UBNT (58.97 -8.79%)
  • Financials:GNBC (20.4 -8.93%)
  • Energy: FRO(5.00 -11.03%)
  • Consumer Staples: CPB(45.4 -11.67%),SFM (19.89 -8.93%)
  • Utilities: EBR(5.61 -10.38%)



 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 9/6/17 23:21 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564
Gapping down
In reaction to disappointing earnings/guidance:

TRVG -20.2%, (lowers guidance), FRAN -14.8%, PLAY -5.7%, NWL -5.1%, JKS -3.5%, UAL -2.9%, (lowers Q3 pre-tax margin guidance to 8-10% from 12.5-14.5%; lowers unit revenue guidance)
Other news:

GDDY -2.8% (to sell 20.05 mln Class A shares in public offering - 20 mln by holders including KKR, Silver Lake)
INSM -2.2% ( to offer $250 million of shares of its common stock)
AYX -2.2% (files for 8 mln share Class A common stock offering by selling stockholders)
NOMD -1.8% (commences public offering of up to approximately 33 mln shares of common stock by certain funds managed by Pershing Square)
TWOU -1.5% (commences proposed public offering of shares of its common stock - includes 3 mln shares offered by the Company and 150K shares offered by the selling stockholders)
IRT -0.7% (commences offering of 12.5 mln share of common stock)
SSRM -0.6% (provides Sep operations update)
Analyst comments:

MPC -0.6% (downgraded to Market Perform from Outperform at Wells Fargo)
08:16 SCANX Gapping up

Gapping up
In reaction to strong earnings/guidance:

EFII +12.1%, DLTH +8.9%, HQY +7.5%, COUP +7.5%, GIII +5.1%, HDS +2.4%, FRED +2.4%, NAV +2.3%, HOME +2.2%, HPE +1.9%, SPB +0.6%, (reaffirms fiscal 2017 guidance during its presentation at the Barclays Conference)
M&A news:

GFF +4.1% (Griffon to explore strategic alternatives for Clopay Plastic Products and confirms acquisition of Emerson's (EMR) ClosetMaid)
MNST +2% (higher in after hours on renewed Coca-Cola (KO) speculation spurred by TheDeal sources)
LDR +2% (to be acquired for $67.25 per share by Fortive (FTV))
Other news:

VSTM +38.8% (reports 'positive' top-line results from the Phase 3 DUO study evaluating the efficacy and safety of duvelisib)
VYGR +34.9% (announces 'positive' results from its ongoing Phase 1b trial of VY-AADC01 in advanced Parkinson's disease)
PTN +21% (enters into collaboration and license agreement with Shanghai Fosun Pharmaceutical)
LTBR +16.1% (Lightbridge and AREVA NP sign a binding Heads of Terms Agreement for a joint venture)
SRPT +15% (SRP-4053 study achieved statistical significance on all primary and secondary biological endpoints)
SKLN +14.2% (entered into an innovative technology partnership with Intalere for the STREAMWAY System)
MEIP +5.1% (enters a license agreement with Presage Biosciences, Inc. for voruciclib)
HIMX +3.1% (continued strength)
ETRM +2.9% (to start FDA post approval study of the vBloc System, a medical device used to treat obesity)
KMDA +2.2% (announces a collaboration for advanced research on Alpha-1 Antitrypsin with a focus on mechanism of action with BGN Technologies)
AFSI +1.9% (provides update on catastrophe reinsurance contracts; new quota share reinsurance contract effective Aug 1, reduces exposure to subsidiary's personal property business)
MGM +1.4% (MGM Growth Properties will purchase the long-term leasehold interest and real property improvements associated with the MGM National Harbor casino resort; MGM Resorts to continue as the operator; MGM Resorts' Board adopts $1 bln stock repurchase program)
NTNX +1.4% (releases slides for ASC 606 investor call)
Analyst comments:

BCRX +13.6% (upgraded to Overweight from Neutral at JP Morgan)
FCAU +5.2% (upgraded to Overweight from Equal Weight at Barclays)
JELD +3.3% (upgraded to Overweight from Neutral at JP Morgan)
W +1.5% (upgraded to Buy from Accumulate last night at Gordon Haskett)
IPG +1.4% (upgraded to Buy from Neutral at Citigroup)
ING +1% (upgraded to Buy from Neutral at Goldman)
NVO +0.7% (upgraded to Neutral from Underperform at BofA/Merrill )
XOM +0.6% (upgraded to Neutral from Sell at UBS)
IAG +0.6% (upgraded to Sector Outperform from Sector Perform at CIBC)


 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 9/7/17 21:36 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564
Gapping up
In reaction to strong earnings/guidance:

RH +33.1%, EGAN +28.6%, GPRO +13.5%, (Guidance), VRNT +5.8%, MTRX +2.8%, CONN +0.8%
M&A news:

TELL +7.8% (enters into agreement to acquire core Haynesville acreage, production and midstream assets)
Other news:

CLIR +18.9% (announced unanimous approval for funding by the Board of the SCAQMD during their September 1, 2017 meeting to demonstrate ClearSign's Duplex products within the Torrance Refinery)
CAB +14.7% (Fed approves the purchase of Cabela's Bank)
AMSC +7.7% (was awarded U.S. Navy contract for insertion of ship protection system on USS Fort Lauderdale, LPD 28)
CUR +7% (receives two patents which broadly protect methods for using neural stem cells to treat neurodegenerative disorders, a key component of the Co's platform)
VVUS +6.7% (EMA granted Orphan Drug Designation to the Company's lead clinical candidate tacrolimus, for the treatment of pulmonary arterial hypertension; co remains on track to hold a pre-IND meeting with the FDA by the end of 2017)
ZAIS +6.2% (confirms receipt of letter from Christian Zugel seeking to pursue discussions to take the Company private by acquiring the issued and outstanding shares of Class A Common Stock at $4.00/share in an all cash transaction)
ITCI +2.8% (announces 'positive' topline data from the first part of an open-label safety switching study in which 302 patients with stable symptoms of schizophrenia were switched from standard-of-care antipsychotic medications to lumateperone),
INSM +1.8% (prices offering of 12,281,000 shares of common stock at $28.50)
GBTC +1.6% (provides update on possible bitcoin cash distribution)
WSM +1.6% (following RH results)
Analyst comments:

APTO +8.5% (upgraded to Buy at H.C. Wainwright)
AZN +3% (initiated with an Outperform at BMO Capital Mkts)
JUNO +2% (initiated with Overweight ratings at Barclays)
BLUE +1.7% (initiated with Overweight ratings at Barclays)
AKS +1.4% (initiated with a Outperform at Macquarie)
ETSY +1.1% (initiated with a Buy at DA Davidson)
CAR +1.1% (Goldman upgrades Rental Car sector)
PX +1% (upgraded to Positive from Neutral at Susquehanna)
ONCE +0.9% (initiated with Overweight ratings at Barclays)
X +0.7% (initiated with a Outperform at Macquarie)


Gapping down
In reaction to disappointing earnings/guidance:

NCS -13.4%, ABM -4.8%, LEG -3.5%, DSGX -1.6%, GIS -1.3%
Other news:

ALNY -12% (provides pipeline update on Fitusiran and Givosiran; Fitusiran dosing suspended due to thrombotic event)
AM -6.9% (prices secondary offering 10 mln common units held by Antero Resources Corp (AR) at $31.45 per unit)
KEM -6% (confirms public secondary offering of 8,416,814 shares of its common stock upon exercise of warrant held by the selling securityholder)
BLDR -3.4% (prices 13,482,177 shares of its common stock at $16.30/share)
NEP -1.4% (announces offering of $300 million in aggregate principal amount of convertible senior notes due 2020)
CELG -0.8% (FDA has placed a partial clinical hold on five trials and a full clinical hold on one trial in the Celgene FUSION program)
NWE -0.7% (establishes 'at-the-market' equity offering program to sell up to of $100 mln of its common stock)
Analyst comments:

RACE -4.1% (downgraded to Underweight from Overweight at Morgan Stanley)
TRHC -3.6% (downgraded to Market Perform from Outperform at Wells Fargo)
SEE -1.5% (downgraded to Neutral from Buy at Citigroup)
CMC -1.1% (initiated with a Underperform at Macquarie)
KAR -0.7% (downgraded to Equal-Weight from Overweight at Stephens)




NLNK NewLink Genetics presents updated data from the ongoing Phase 2 NLG2103 study of indoximod in combination w/ KEYTRUDA (owned by Merck MRK) (7.79 )

"Combined Inhibition of the IDO and PD-1 Pathways Improves the Response Rate for Patients with Advanced Melanoma", showed an improvement over previously reported results presented at the AACR Annual Meeting 2017 for both the Complete Response rate and the Overall Response Rate for patients1 who received indoximod plus pembrolizumab. Evaluable patients were defined as those having at least one on-treatment imaging study."
Key findings in the updated data reported today:
Improvement in Complete Response (CR) to 20% (10/51 patients) compared to CR of 12% (6/51 patients)
The Progression-Free Survival (PFS) by RECIST criteria was 56% at one year with median PFS (mPFS) of 12.9 months


 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 9/10/17 21:33 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564
Gapping up
In reaction to strong earnings/guidance:

ZUMZ +14.8%, (reports earnings and Aug comparable sales increased 7.4%), AGX +11.8%, BV +8.4%, CLDR +3.7%, RDFN +3.3%, OKTA +3.2%, REVG +2.4%
Select Cyber security names related names showing strength:

SYMC +2.5%, FEYE +2%, CHKP +1.5%, CYBR +1%, HACK +0.6%, PANW +0.5%
Other news:

KURA +26.3% (announces its Phase 2 trial for tipifarnib in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck met its primary endpoint)
OPGN +8.3% (presents results on the Acuitas AMR Gene Panel u5.47 at the 2017 ASM/ESCMID Conference)
AVEO +6% (continued strength)
CLVS +4% (ARIEL3 study successfully achieved its primary endpoint)
IDRA +2% (reports pre-clinical data from its ongoing intratumoral IMO-2125 development program)
STM +1.7% (Euronext announces annual review results on the CAC family indices -- to include STMicroelectronics in the CAC 40, exclude Nokia (NOK))
SNY +0.5% (Sanofi and Regeneron (REGN) receive FDA Breakthrough Therapy Designation for Cemiplimab)
Analyst comments:

TTWO +1% (initiated with a Buy at Goldman)
EA +0.8% (initiated on the Conviction Buy List at Goldman)

Gapping down
In reaction to disappointing earnings/guidance:

TNTR -21.9%, AOBC -17.2%, CHKE -16.1%, KR -6.2%, SAIC -5.9%, PAY -5%, FIZZ -1.8%, SIGM -1.6%, TLRD -1.2%
Other news:

EFX -13.1% (announced cybersecurity incident potentially impacting approximately 143 million U.S. consumers; no evidence of unauthorized access to core consumer or commercial credit reporting databases)
LAND -4% (commences common stock offering; size not disclosed)
INCY -2.5% (proposes public offering of 4,945,000 shares of common stock)
NOK -2.1% (Euronext announces annual review results on the CAC family indices -- to include STMicroelectronics in the CAC 40, exclude Nokia (NOK))
TRTN -1.4% (to offer 5.35 mln common shares to be sold by the Company at a price of $32.75/share)
KTOS -0.6% (prices 14 mln shares of common stock at $12.25 per share)
AYX -0.5% (prices follow-on offering of 8 mln shares of common stock by selling shareholders at $21.25 per share)
Analyst comments:

CMG -2.1% (downgraded to Underperform from Market Perform at Cowen)
CTLT -1.3% (downgraded to Sector Weight from Overweight at KeyBanc Capital Mkts)
HDS -1% (downgraded to Neutral from Outperform at Credit Suisse)
PEP -0.5% (downgraded to Neutral from Outperform at Credit Suisse)

The following are this week's top 20 percentage gainers and top 20 percentage losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top 20 % gainers
Healthcare: INSM (30.04 +144.43%), NLNK (17.67 +126.83%), NH (4.12 +54.89%), ADAP (8.93 +35.71%), LBIO (7.3 +21.67%), BCRX (5.85 +17%), ITCI (21.39 +14.57%), RGNX (25.7 +13.47%), ABBV (85.34 +13.15%)
Materials: FRTA (3.82 +14.37%), BMS (49.22 +13.54%)
Industrials: NAV (38.89 +12.66%)
Consumer Discretionary: RH (70.65 +45.64%), CONN (23.1 +18.77%), FRED (6.95 +14.5%), GPRO (10.26 +14%), CAB (60.93 +13.36%)
Energy: MTRX (14.2 +16.87%), FRO (5.69 +13.8%)
Utilities: EBR (6.33 +12.83%)
This week's top 20 % losers
Healthcare: ALNY (73.69 -17.12%), CLLS (27.07 -15.88%), MNK (35.33 -14.19%), CLVS (67.17 -14.17%)
Industrials: NCS (13.85 -17.31%), TRTN (31.87 -15.93%)
Consumer Discretionary: AOBC (13.92 -15.74%)
Information Technology: TRVG (10.96 -29.34%), LEJU (1.47 -19.23%), SAIC (61.06 -17.95%), KEM (20.44 -16.09%), HLIT (2.9 -14.71%)
Financials: UVE (17.85 -17.17%), HRTG (9.37 -16.79%), AHL (38.15 -15.97%)
Energy: SDRL (0.22 -22.82%), REN (24.28 -18.06%), CRZO (11.38 -16.81%)
Telecommunication Services: GSAT (1.63 -18.5%)


Last edited by sunnyday on 9/11/17 21:51, edited 1 time in total

 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 9/11/17 21:49 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564
Gapping down
In reaction to disappointing earnings/guidance:

N/A.
Select metals/mining stocks trading lower:

HMY -3.4%, KGC -2.7%, AUY -2.3%, GOLD -1.6%, GDX -1.6%, GG -1.6%, SLV -1.6%, NEM -1.5%, NEM -1.5%, ABX -1.5%, GFI -1.3%, AG -1.1%, RGLD -0.9%, GLD -0.9%
Other news:

ACHN -25.3% (Achillion Pharma receives termination notice of Worldwide Collaboration for Hepatitis C With JnJ's Janssen)
Analyst comments:

OC -2.6% (downgraded to Neutral from Buy at Nomura)
STX -2.5% (downgraded to Sector Perform from Outperform at FBN Securities)
SNAP -1.6% (downgraded to Hold from Buy at Deutsche Bank)
MGM -1.4% (downgraded to Hold from Buy at Deutsche Bank)
GRUB -1.2% (downgraded to Neutral from Outperform at Credit Suisse)
NWL -0.8% (downgraded to Hold from Buy at Jefferies)
KR -0.7% (downgraded to Hold from Buy at Deutsche Bank)
08:41 SCANX Gapping up

Gapping up
In reaction to strong earnings/guidance:

N/A.
Select actively traded names showing strength:

EA +1.7%, TSLA +1.6%, AMD +1.3%, AAPL +1.2%, NVDA +1%, NFLX +1%, FB +0.7%
Select Chinese related stocks trading higher:

YNDX +2%, BABA +1.3%, BIDU +1.2%, MOMO +1.2%, WB +0.6%
Other news:

MRNS +29.8% (announces top-line data from the Phase 2 open-label study in patients with CDKL5 disorder support advancing ganaxolone into a definitive late-stage clinical trial)
CTRV +23.5% (announces that the FDA has approved an Investigational New Drug Application in the U.S. for its lead HBV compound, TXL for the treatment of chronic hepatitis B)
IDRA+20.5% (presents positive Phase 1 data for Intratumoral IMO-2125 )
RNN +13% (presents preliminary efficacy data from the Ongoing Phase IIa Clinical Trial of RX-3117 )
TEVA +11.4% (present late-breaking present data presented highlighting primary and secondary outcome measure results from chronic and episodic migraine Phase III clinical trials; also appointed new CEO)
RXDX +9.5% (confirms completion of enrollment of the efficacy data sets for both the NTRK tissue-agnostic cohort and the ROS1 NSCLC cohort to support dual NDA submissions in 2018)
ARRY +7.5% (present Phase 3 COLUMBUS Part 2 results in BRAF-Mutant Melanoma)
VKTX +4.3% (announces results from a gene expression analysis conducted as part of its recently completed study of VK2809),
INO +3.8% (announces that an interim data analysis for its INO-5150)
EXEL +2.2% (Exelixis and Ipsen report results from Phase 2 CABOSUN trial of Cabozantinib versus Sunitinib confirms primary endpoint analysis per investigator)
INCY +2% (Incyte and Merck present progression-free survival data from ECHO-202 Trial )
CBIO +2% (issued patents covering its coagulation Factor IX hemophilia product candidate from the State Intellectual Property Office (SIPO) in China)
AZN +1.7% (presents results from a subgroup analysis of the SIROCCO and CALIMA Phase III trials)
IONS +1.5% (presents new data from IONIS-STAT3-2.5Rx demonstrating antitumor activity in combination with Imfinzi)
Analyst comments:

ATI +3.4% (upgraded to Buy from Underperform at BofA/Merrill )
FEYE +2.8% (upgraded to Overweight from Equal-Weight at Stephens)
MA +1.7% (upgraded to Buy from Neutral at Guggenheim)
MU +1.1% (initiated with a Outperform at FBN Securities)
TXT +0.9% (upgraded to Buy from Hold at Drexel Hamilton)


 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 9/12/17 22:37 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564
Gapping up
In reaction to strong earnings/guidance:

PPHM +8%, LAYN +7.1%, PRGS +2.6%, (Q3 pre-announcement)
M&A news:

TEVA +7.4% (Teva Pharma enters into a definitive agreement under which CooperSurgical (COO) will acquire PARAGARD; also receives FDA Priority Review for first line use of TRISENOX)
GIMO +1.6% (Hearing sell side out suggesting between $47-60/share takeout could be in the works)
Other news:

ALDX +47.5% (announces positive results from Dry Eye Disease Phase 2a Clinical Trial; Statistically and clinically significant improvement across multiple sign and symptom endpoints)
HTBX +9.3% (granted a Type C meeting with the FDA to discuss the registrational pathway for our non-small cell lung cancer trial with HS-110 in combination with Bristol Myers-Squibb's (BMY) Opdivo based upon maturing Phase 2 data)
ZFGN +4.7% (presents data for ZGN-1061 )
DWDP +2.7% (completes review of the portfolio composition of the three intended independent companies)
EYES +2.4% (Director Gregg Williams discloses 41.64% active stake)
WDC +1.9% (seeing after hours strength on reports of winning bid for Toshiba (TOSBF) chip unit)
GPRO +1.9% (continued strength)
TTD +1.5% (continued strength)
MU +1.2% (ahead of AAPL product event)
AMD +1% (ahead of AAPL product event)
AAPL +0.8% (ahead of AAPL product event)
Analyst comments:

CTIC +8% (initiated with a Buy at Jefferies)
DB +3.5% (upgraded to Outperform from Market Perform at Keefe Bruyette)
AA +2.5% (upgraded to Buy from Hold at Deutsche Bank)
MTZ +2.2% (upgraded to Buy from Hold at Deutsche Bank)
CMCSA +1.5% (upgraded to Buy from Neutral at MoffettNathanson)
NKE +0.8% (initiated with a Outperform at Bernstein)

Gapping down
In reaction to disappointing earnings/guidance:

LMNR -9.7%, ADXS -1%
Other news:

SAGE -25.5% (reports top-line results from its Phase 3 STATUS Trial of brexanolone)
MBVX -16.7% (greed to sell approximately 4 mln shares of its common stock for gross proceeds of approximately $2.0 million ($0.50/share))
HIIQ -16.5% (continued weakness following management update conference call after the close)
BCRX -9.7% (to sell $80 mln of its common stock in an underwritten public offering)
BIP -5% (Brookfield Infrastructure to issue 16,628,000 L.P. units on a bought deal basis to a syndicate of underwriters at $42.10 per L.P. unit)
BG -3% (enters into a definitive agreement to acquire a 70% ownership interest in IOI Loders Croklaan from IOI Corporation Berhad for $946 mln)
PTLA -2.6% (plans to offer $300 mln of its common stock in an underwritten public offering )
FDC -2.1% (confirms that New Omaha Holdings intends to offer for sale in an underwritten secondary offering 85 mln shares of Class A common stock pursuant to the registration statement)
CPT -1.5% (prices 4.75 mln common sharesfor gross proceeds of $445.3 mln)
EFX -1.1% (continued weakness)
Analyst comments:

PDS -4.8% (downgraded to Neutral from Overweight at JP Morgan)


 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 9/13/17 22:46 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564
Gapping down
In reaction to disappointing earnings/guidance:

AMRK -15%, FARM -9.9%, RLGT -5.5%
M&A news:

WDC -3.2% (Toshiba signs MOU with Bain Cap'l for sale of TMC)
Other news:

ITEK -14.3% (Inotek Pharmaceuticals to merge with with US-based gene therapy company Rocket Pharmaceuticals - will host a conference call Sept 13 at 8:30am ET)
TCMD -4.6% ( announces 2.7 mln share secondary offering by stockholders)
CLDX -3.8% (announces the resignation of Chief Medical Officer Thomas Davis effective September 29 )
AGNC -3.2% (prices 24.5 mln shares of common stock at for gross proceeds of $510.8 mln)
PTLA -2% (prices 6.35 mln shares of common stock at $55.00 per share)
ZAGG -1.2% ( subsidiary mophie will have universal wireless charging pad for iPhone 8, iPhone 8 Plus and iPhone X )
Analyst comments:

ON -1.9% (downgraded to Neutral from Buy at Goldman)
AVP -1.2% (initiated with a Underperform at Jefferies)
WLL -1.1% (downgraded to Underweight from Equal-Weight at Morgan Stanley)
KLAC -1% (downgraded to Neutral from Buy at Goldman)
08:17 SCANX Gapping up

Gapping up
In reaction to strong earnings/guidance:

CBRL +2.4%, AGTC +1%
M&A news:

SNAK +32.8% (to sell its frozen business for $50 mln; strategic and financial review remains ongoing)
JWN +6% (reports the company to go private)
Select JWN peers showing strength:

DDS +4%, SHLD +1.3%, SHOS +1.2%, M +1.2%, JCP +0.7%
Other news:

BVXV +18.9% (continued strength)
ALDX +12.8% (continued strength)
CNC +5.6% (Centene to acquire substantially all of the assets of Fidelis Care for $3.75 bln - will become Centene's health plan in New York State; companies to host conference call at 5:00 PM ET today)
ZFGN +4.7% (announces initiation of ZAF-1061-201, the Co's Phase 2 clinical trial evaluating ZGN-1061 in patients with type 2 diabetes)
OTIC +4.1% (unveils set of immediate actions to preserve capital, extend its cash runway, and build shareholder value)
GTXI +3.6% (top-line results 'demonstrating that a daily dose of enobosarm 3 mg substantially improved stress urinary incontinence')
TEX +3.4% (Marcato's McGuire discusses Terex position on Delivering Alpha)
FOLD +3.4% (top-line Phase 3 results for SD-101 in epidermolysis bullosa; study did not meet primary endpoints)
BCRX +3.3% (prices 15,533,981 shares of its common stock at $5.15 per share)
PSTI +3.3% (has been issued two new patents by Hong Kong Patents Registry for its cell therapy products relating to two of the company's leading indications, Critical Limb Ischemia (CLI) and muscle regeneration)
AKCA +3.2% (Akcea Therapeutics and Ionis announce filing of New Drug Submission for Volanesorsen to Health Canada - an investigational medicine for the treatment of familial chylomicronemia syndrome)
XL +2% (receives full internal model approval from the Bermuda Monetary Authority to calculate the Company's enhanced capital requirements in substitution of the Bermuda Solvency Capital Requirement standard formula)
ARRY +1.8% (Point72 Asset Management increases passive stake to 5.4%)
CLVS +1.3% (publication of data from the Phase 3 ARIEL3 study of rucaparib for maintenance treatment of advanced ovarian cancer in The Lancet)
BBRY +1.3% (BlackBerry and Timex Group enter into a patent license agreement)
FGEN +1.3% (announces 'positive' results from the company's Phase 2b study in patients with idiopathic pulmonary fibrosis)
NCS +1.1% (Director purchased 30K shares on 9/11)
JUNO +1% (granted orphan drug designation by the FDA for its compound for the treatment of follicular lymphoma)
Analyst comments:

FINL +4.6% (upgraded to Positive from Neutral at Susquehanna)
SQM +3.4% (upgraded to Buy from Neutral at BofA/Merrill)
ADMP +2.8% (initiated with a Outperform at Raymond James)
AMAT +1.6% (upgraded to Buy from Neutral at Goldman)
MU +0.9% (upgraded to Buy from Neutral at Goldman)


 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 9/14/17 20:30 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564
Gapping down
In reaction to disappointing earnings/guidance:

N/A
Other news:

SMMT -16.5% (prices offering of 1,459,000 ADS's at $12.00 per ADS)
BVXV -14.8% (prices follow-on offering of 1.5 mln ADSs at $6.00 per ADS)
ARRY -7.9% (commences $175 mln common stock offering; files mixed securities shelf offering)
EPZM -3.8% (prices 9.18 mln common stock offering at $15.285/share)
MGI -3.7% (following Canyon / LSCC news - deal with BABA / Ant may also be scrutinized)
USFD -3.2% (confirms offering of 40 mln shares of common stock by investment funds associated with Clayton, Dubilier & Rice and Kohlberg Kravis Roberts )
WLH -2.6% (proposed secondary offering of 3,322,666 shares of Class A common stock offered by Paulson & Co)
FDC -2.4% (prices secondary offering by selling shareholders of 85 mln shares of common stock at $17.75 per share)
GNW -1.3% (following Canyon / LSCC news - overseas deal may also be scrutinized)
BABA -1.2% ( Jack Ma affiliated entities adopted pre-arranged share sales plan for the sale of up to 16 million shares of the Company over a 12-month period commencing in October 2017)
KONA -1.2% (modestly pulling back)
TIF -1.1% ( indicated lower on block trade pricing)
Analyst comments:

HTZ -6% (downgraded to Underweight from Equal-Weight at Morgan Stanley)
OPK -3.2% (downgraded to Neutral from Overweight at JP Morgan)

Gapping up
In reaction to strong earnings/guidance:

UNFI +6.4%, PCYG +5.5%, LAKE +4.3%
M&A news:

ALV +9.5% (initiates strategic review with the intent to create separate companies of its current business segments, Passive Safety and Electronics)
THC +7.8% (WSJ reporting the company is considering sale; Glenview confirms plans to engage with the Board in connection with the CEO transition and search/Board refreshment)
Other news:

HALO +19.1% (HALO and BMY enter collaboration/license agreement to develop Bristol-Myers Squibb medicines using Halozyme's ENHANZE technology)
RETA +5.1% ( confirms it received orphan drug designation for omaveloxolone for the treatment of malignant melanoma )
AAC +3% (ticking higher-to increase payor and geographic diversification with agreement to acquire AdCare in New England )
CYH +2.9% (higher with THC)
RDUS +2.4% ( slightly higher after 10% owner Biotech Growth disclosed purchase of another 50K shares)
SALT +2.2% (authorized the repurchase of up to $50.0 million of the Company's common stock in open market or privately negotiated transactions)
PLUG +1.7% (in sympathy with BLDP)
HCA +1.3% (higher with THC)
FCAU +1.3% (reports European sales increased 9.8% in Aug)
BLDP +1.1% (accepted Letter of Intent to provide FCveloCity-HD 100-kilowatt fuel cell engines to power 8 ExquiCity tram-buses being built by Van Hool NV during the second half of 2019), .
Analyst comments:

RARE +4% (upgraded to Outperform from Neutral at Wedbush)
NUE +1.4% (upgraded to Buy from Neutral at Citigroup)


 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 9/17/17 23:43 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564
Gapping down
In reaction to disappointing earnings/guidance:

ORCL -4%
Other news:


TTOO -32.1% (commences common stock offering)
SAVE -1.8% (reported August Traffic (revenue passenger miles) +20.6% y/y on a capacity (available seat miles) increase of 21.9%; expect Irma impact to be significant )
MTW -1.7% (plans to undertake reverse stock split of Manitowoc's common stock at a ratio of 1-for-4), .
Analyst comments:

CCL -2.5% (downgraded to Neutral from Outperform at Credit Suisse),
AAL -2.2% (downgraded to Neutral from Overweight at JP Morgan),
UAL -2.2% (downgraded to Neutral from Overweight at JP Morgan),
SAVE -1.8% (downgraded to Neutral from Overweight at JP Morgan),
AYI -1.3% (downgraded to Market Perform from Outperform at Wells Fargo),
ALNY -0.6% (initiated with a Reduce at Instinet)

Gapping up
In reaction to strong earnings/guidance:

LPTH +18.3%, ASPU +3.9%, KANG +1.3%
Other news:

MRTX +82.1% (presents 'positive' preliminary data from on-going clinical trials of sitravatinib in non-small cell lung cancer), TNXP +9.6% (receives a European patent protecting the use of Tonmya for the treatment of PTSD), OPNT +8.2% (provides an update on NARCAN Nasal Spray), MBOT +4.8% (announced that Intellectual Property India granted patent No. 286765, covering the Company's TipCAT technology platform), GNW +2.8% (Virginia State Corporation Commission, Bureau of Insurance, approved the proposed acquisition of control by Oceanwide of Genworth's Virginia-domiciled insurance companies), ARRY +2.8% (prices offering of 20,930,232 shares of its common stock at of $10.75 per share), OCLR +2.1% (initiated after hours with a Strong Buy at Raymond James), MRNS +1.7% (prices 9,333,334 common stock offering at $3.75/share), BTX +1.7% (ticking higher; announced the successful conclusion of the challenge to two key patents before the European Patent Office Opposition division), TWO +1.6% (Two Harbors Investment declared special dividend to distribute shares of Granite Point Mortgage Trust (GPMT) and approved a one-for-two reverse stock split), .
Analyst comments:

FSLR +3.1% (upgraded to Buy from Hold at Deutsche Bank),
WEN +2.3% (upgraded to Buy from Neutral at Longbow),
OCLR +2.1% (initiated with a Strong Buy at Raymond James),
NVDA +1.7% (target raised to $250 from $180 at Evercore ISI ),
LUV +1.1% (upgraded to Overweight from Neutral at JP Morgan),

This week's top 20 % gainers
Healthcare: HALO (16.25 +23.95%)
Materials: SQM (58.06 +19.86%), FTK (5.7 +18.75%)
Industrials: BLDP (4.43 +33.03%), BW (3.55 +28.62%)
Consumer Discretionary: NCMI (6.87 +33.4%), AMC (16.95 +26.97%), TLRD (14.55 +19.36%), BZH (17.61 +18.75%), PIR (5.2 +18.18%)
Information Technology: UCTT (26.96 +20.84%), CSOD (41.07 +19.81%), BZUN (37.7 +19.46%)
Financials: HRTG (12.87 +37.35%), UVE (21.25 +19.05%)
Energy: REN (30.11 +24.01%), TTI (2.49 +21.46%), CRZO (13.78 +21.09%), EMES (7.93 +20.7%)
Telecommunication Services: I (4.64 +17.47%)
This week's top 20 % losers
Healthcare: ADXS (4.81 -35.09%), SAGE (62.36 -28.32%), NLNK (12.67 -28.3%), GKOS (31.4 -25.24%), ACHN (3.7 -24.64%), CRIS (1.72 -20.37%), ICPT (94.88 -18.84%), LXRX (12.37 -16.02%), BEAT (32.7 -14.95%), HZNP (12.11 -12.44%), BCRX (5.15 -11.97%)
Materials: AGI (7.4 -12.43%), USCR (70.7 -11.4%), CSTM (9.7 -10.6%), CLF (7.13 -10.43%)
Industrials: EFX (92.98 -24.55%), TRU (41.61 -12.4%), HTZ (20.57 -11.26%)
Consumer Discretionary: IRBT (79.81 -16.14%)
Information Technology: VDSI (11.05 -10.53%)


 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 9/18/17 21:51 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564
Gapping down
In reaction to disappointing earnings/guidance:

STNG -5.7%
Select metals/mining stocks trading lower:

HMY -4.7%, GFI -1.8%, AUY -1.4%, GOLD -1.1%, GDX -0.8%, NEM -0.8%, GLD -0.7%
Other news:

HMNY -13.6% (files for approx 9.1 mln share common stock offering by holders)
TISI -5.9% (CEO steps down)
FRED -3.1% (amends short-term shareholder rights plan to protect the ability to utilize net operating losses)
CLDR -2.1% (files $175 mln mixed securities shelf offering)
RYAAY -1.8% (after acknowledging that a scheduling mix up will force it to cancel hundreds of flights over the coming weeks), .
Analyst comments:

BRKS -4.3% (downgraded to Hold from Buy at Needham)
CRUS -2% (initiated with a Underperform at BofA/Merrill)

Gapping up
In reaction to strong earnings/guidance:

HUN +1.9%, (expects 'strong' Q3 results, after excluding the Pigments and Additives division, which will now be reported in discontinued operations)
M&A news:

SSNI +24.6% (to be acquired by Itron (ITRI) for $16.25/share)
OA +19.8% (confirms deal to be acquired by Northrop Grumman (NOC) in a $9.2 bln deal)
RAD +4.2% (Walgreens Boot Alliance said to plan to revise its pending agreement to acquire Rite-Aid (RAD) stores in effort to gain regulatory approval for the proposed deal, according to Bloomberg)
UPL +2.3% (largest stockholder Firm Tree Partners announces its intention to immediately engage with Co management to pursue value-maximizing strategic alternatives)
Select China related names showing strength:

MOMO +1.1%, WB +1%, JD +0.8%, BIDU +0.7%
Other news:

NBRV +101.2% (announces 'positive' results from the lefamulin evaluation against pneumonia trial)
PSTI +17.9% (FDA has granted Fast Track Designation to the co's ongoing Phase III study of PLX-PAD cells for the treatment of Critical Limb Ischemia in patients ineligible for revascularization)
PTIE +14.4% (receives an approx. $1.8 mln research grant from the NIH and $2.2 mln grant from the National Institute on Drug Abuse)
BLDP +5.4% (received a purchase order from Nisshinbo Holdings)
SNGX +3.3% (receives from the NCI a two-year, approx. $1.5 mln SBIR grant to support its Phase 3 study evaluating SGX301)
NLNK +2.6% (modestly rebounding following last weeks 28% loss)
KTOS +2.3% (S&P upgraded Kratos Defense & Security Solutions Inc. to 'B' on expected debt repayment, outlook positive)
TRXC +2% (responds to the FDA's Additional Info request related to its Senhance Surgical Robotic System 510(k) submission; continues to expect 510(k) clearance in 2017), TNXP +1.9% (files to withdraw registration statement on Form S-3 filed on Aug 11)
MRTX +1.8% (continued strength)
RDHL +1.6% (receives a NOA from the USPTO for a new patent covering the use of two of YELIVA and MUSPRON in combination with a known antibiotic)
NOK +1.1% (receives decision in patent license arbitration with LG Electronics (LGEAF); expects that revenue for the agreement will be recognized in Q3)
LB +0.9% (authorizes $250 mln share repurchase program)
Analyst comments:

ARWR +8.5% (upgraded to Outperform from Mkt Perform at William Blair)
PAH +3% (upgraded to Buy from Hold at SunTrust)
NVDA +2.1% (target raised to $210 from $185 at BofA/Merrill )
YUMC +1.7% (upgraded to at )
CAT +1.6% (upgraded to Buy from Neutral at UBS)
INST +1.6% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
AMAT +1.4% (upgraded to Outperform at RBC Capital Mkts)
ASML +1.2% (upgraded to Positive from Neutral at Susquehanna)
CMPR +1% (upgraded to Outperform from Mkt Perform at Barrington Research)
SONC +0.8% (initiated with a Buy at Citigroup


 
 Profile  
Reply to topic 
 Post subject: Re: 盘前个股动态2016
PostPosted: 9/19/17 22:05 
Offline 模拟帐户

Joined: 8/8/10 22:40
Posts: 1564
Gapping down
In reaction to disappointing earnings/guidance:

APOG -2.2%
M&A news:

SNCR -18.8% (Siris Capital Group affirms 12.93% active stake, informs the Company that they are no longer interested in pursuing an all-cash acquisition of the Company and, accordingly, the indication of interest set forth in the June 22 Letter is withdraw)
Other news:

FOMX -11.6% (Foamix director and advisor entered into an individual share trading plan in accordance with Rule 10b5-1)
MDWD -9.9% (prices underwritten public offering of 4,400,000 of its ordinary shares at a price to the public of $5.00/share)
MUX -8.6% (announces bought deal of $40.5 mln -- includes 18 mln shares and warrants to buy up to 9 mln shares at $2.25 per share and associated one-half common stock warrant)
SUPN -7.4% (announced the outcome of the planned interim analysis from the first Phase III clinical trial on SPN-810; says lower dose of SPN-810 trial will be eliminated)
BECN -4.7% (commences $300 mln common stock offering; also files for common stock shelf offering )
HAS -2.4% (continued weakness on Toys R Us bankruptcy)
EFX -1.8% (pulling back in after hours trade on reports that the company had security breach earlier than disclosed)
PAA -1.3% (Valero Energy and Plains All American Pipeline (PAA) mutually agreed to terminate agreement providing for the acquisition by a subsidiary of Valero of two petroleum storage and distribution terminals)
BEAT -1.3% (continued weakness; also Board of Directors determined that the Company hold an advisory vote to approve executive compensation annually until the next required stockholder vote on the frequency of such votes)
FRSH -1.1% (appoints CFO Mark Hutchens as COO effective immediately; Hutchens will continue in his role as CFO until a qualified replacement is found)
Analyst comments:

UAA -2.9% (downgraded to Underperform from Market Perform at Wells Fargo)
DMTX -1.7% (downgraded to Sell from Neutral at Citigroup)
NKE -1.5% (downgraded to Neutral from Positive at Susquehanna)
TSLA -0.9% (initiated with a Underperform at Jefferies)

Gapping up
In reaction to strong earnings/guidance:

SCS +6.6%, AZO +2.6%
M&A news:

BOBE +5.7% (Post Holdings (POST) to acquire Bob Evans Farms for $77.00/share)
RAD +2.2% (confirms regulatory clearance for an amended and restated asset purchase agreement with Walgreens Boots Alliance (WBA))
JONE +1.4% ( Fir Tree Partners calls on Jones Energy to pursue value-maximizing strategic alternatives)
Other news:

STAF +62.1% (refinances balance sheet, announces closing of two acquisitions)
PRQR +5.9% (announces that investigational drug QR-313 for dystrophic epidermolysis bullosa has received orphan drug designation from the FDA)
REXX +5.5% (provides an update for its Moraine East Area operations, remains on target to meet its Q3 production guidance of 171.0 -- 181.0 MMcfe/d and its FY 17 exit rate production growth rate guidance of 15% - 20%)
DRNA +5% (Bain Capital Life Sciences Fund discloses increased active stake),
NBRV +5% (continued strength; also commences an underwritten public offering of $80.0 mln of ordinary shares)
UBNT +3.2% (adds $100 mln to repurchase program, updates Q1 guidance, reaffirms FY18 outlook)
NOMD +3.1% (Elliott Associates discloses 5.7% passive stake)
KTOS +2.1% (Kratos Defense and Security deploys the World's First autonomous vehicle approved and supporting live roadway operation in Colorado )
SINA +1.7% ( Aristeia Capital confirms has nominated two independent candidates for election to Sina's Board to immediately evaluate and help execute opportunities)
FOLD +1.7% (FDA has granted Fast Track designation for the oral precision medicine migalastat)
M +1.4% (Macy's details plans to hire approximately 80,000 seasonal associates)
Analyst comments:

MRTX +4.6% (initiated with a Outperform at Oppenheimer)
QDEL +3.9% (upgraded to Overweight from Neutral at Piper Jaffray)
KORS +3% (upgraded to Outperform from Perform at Oppenheimer)
GPS +2.2% (upgraded to Neutral from Underperform at Credit Suisse)
ACIA +1.9% (initiated with a Buy at MKM Partners)
MLCO +1% (upgraded to Buy from Neutral at Nomura)
NTAP +0.9% (upgraded to Buy from Neutral at UBS)
AAPL +0.5% (target raised to $194 from $182 at Morgan Stanley)


 
 Profile  
Reply to topic 
Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 544 Posts ]  Go to page Previous  1 ... 33, 34, 35, 36, 37  Next

Home 


Who is online

Users browsing this forum: No registered users and 2 guests


You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot post attachments in this forum

Search for:

Batch Generator
Hutong9 SizzlingStock GaoFamily  Hearty  TT  股通 财籽 GrusInvest E.T. Yahoo Google msn 大千 未名 外汇牛人邦 CNFinance 华人 investern optionpain YangCai 司空金融网


This site is mainly for stock market discussion, it does not provide any investment advice. It is not suggested to rely on posts here for investment decision.
本网站主要作为股市讨论用途,并不提供任何投资建议。请不要将本站内容作为投资依据,否则风险自负。

钱多多股票论坛 - Trader1688.com© Powered by phpBB © 2002, 2006 phpBB Group